Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis
The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
Background: Preclinical data suggest that metformin may reduce breast cancer incidence and improve cancer prognosis. However, the current evidence in observational studies is inconclusive. A systematic review and meta-analysis was conducted to assess the effect of metformin on the incidence of breast cancer and all-cause mortality in patients with type II diabetes (T2D). Methods: A literature search was performed on Medline, EMBASE, and the Cochrane library from inception to November 2016. Outcomes were incidence of breast cancer and all-cause mortality. Risk of bias and overall certainty of evidence was assessed using the Newcastle-Ottawa Scale and Grading of Recommendations Assessment, Development, and Evaluation (GRADE), respectively. Meta-analyses were performed using the most fully adjusted ORs or HRs and 95% confidence intervals (95% CI) as effect measures. Results: A total of 12 observational studies were included for breast cancer incidence and 11 studies for all-cause mortality. No significant association was found between metformin exposure and incidence of breast cancer (OR = 0.93; 95% CI, 0.85–1.03; I2 = 35%). A 45% risk reduction was observed for all-cause mortality (HR = 0.55; 95% CI, 0.44–0.70; I2 = 81%). Presence of publication bias is strongly suspected for both outcomes using Egger's funnel plots. Conclusions: The use of metformin may improve overall survival in patients with T2D and breast cancer. No effect of metformin on the incidence of breast cancer was observed. Interpretation of results is limited by the observational nature of the studies and resulting biases. Impact: Clinical trials are warranted to determine the role of metformin in breast cancer risk reduction and prognosis. Cancer Epidemiol Biomarkers Prev; 27(6); 627–35. ©2018 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is an inverse association between the risk of prostate cancer and DM,1774 although the use of antihyperglycemic agents may have diminished the apparent DM-associated risk in epidemiologic studies.1775”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1774]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“Publication bias was assessed by using the Egger's funnel plot (43).”
Method(2014) · Medical Entomology and Zoology · Cited by 17,633
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681 · cited 4×
“Reasons to raise certainty include largemagnitude of effect, dose– response relation, and adjustment of all plausible residual confounding (39, 40).”
BackgroundMethodInfluentialGRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285 · cited 3×
“Reasons to raise certainty include largemagnitude of effect, dose– response relation, and adjustment of all plausible residual confounding (39, 40).”
BackgroundMethodSelf-citationMarginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581 · cited 1×
“When time-dependent confounders are detected, standard statistical models cannot estimate the true causal effect of time-varying treatment (66, 67).”
BackgroundReprint—Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & and the PRISMA Group (2009) · Physical Therapy · doi:10.1093/ptj/89.9.873 · Cited by 2,486
Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments
Lo, C. K.-L., Mertz, D., & Loeb, M. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-45 · Cited by 2,477 · cited 1×
“Risk of bias assessment The Newcastle-Ottawa Scale (NOS) for nonrandomized studies was used to assess risk of bias (RoB) for the included studies (36, 37).”
MethodGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · cited 1×
“Type II diabetes (T2D) and cancer are two common chronic diseases that decrease quality of life and survival (1, 2).”
BackgroundBiodiversity on the Rocks: Macrofauna Inhabiting Authigenic Carbonate at Costa Rica Methane Seeps
Levin, L. A., Mendoza, G. F., Grupe, B. M., Gonzalez, J. P., Jellison, B., Rouse, G., Thurber, A. R., & Waren, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131080 · Cited by 2,167
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Research works printed but not linked: 2
- Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
- Altman, 1991, Inter-rater agreement, Pract Stat Med Res, 5, 403
Cited by
Epidemiological characteristics of and risk factors for breast cancer in the world
Momenimovahed, Z., & Salehiniya, H. (2019) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s176070 · Cited by 1,050
“The use of metformin can improve the overall survival rate in people with breast cancer and type II diabetes.(158) According to EPIC, in addition to endocrine factors, in women with higher levels of IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3) than normal, the risk of developing breast cancer is si…”
BackgroundPI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Machine and deep learning approaches for cancer drug repurposing
Issa, N. T., Stathias, V., Schürer, S., & Dakshanamurthy, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.011 · Cited by 274
“The repurposing potential for metformin as an anti-cancer therapeutic has also been confirmed in several preclinical and epidemiological studies for breast cancer (90).”
BackgroundCancer Progress and Priorities: Breast Cancer
Houghton, S. C., & Hankinson, S. E. (2021) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1193 · Cited by 163
Metadata
- Authors
- Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P.
- Affiliations
- McMaster University (CA)
- Instituto Nazionale Tumori Regina Elena (IT)
- Corresponding author
- Muti, Paola
- ORCID
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2018-05-31
- Volume
- 27
- Issue
- 6
- Pages
- 627-635
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2795771650
- Cited by
- 117
- References
- 80
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 13 · 2023: 12 · 2022: 17 · 2021: 18 · 2020: 19 · 2019: 19 · 2018: 6
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- metformin, breast cancer incidence, breast cancer mortality, type 2 diabetes, all-cause mortality, cancer risk reduction, cancer prognosis, publication bias
- MeSH terms
- Breast Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Metformin, Prognosis, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1158/1055-9965.epi-17-0936
- The paper
- Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P. (2018). Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-17-0936
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.